Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Provenge Review In 2008 Hinges On IMPACT Interim Analysis

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.

You may also be interested in...



House Panel Denies Members' Request To Investigate Provenge Advisory Committee

Bipartisan group looking to investigate conflict of interest at an FDA advisory committee on Provenge were stopped in their tracks by a letter from Energy & Commerce Committee leaders.

Life Beyond Provenge: Dendreon Plans To Move First Small Molecule Into The Clinic

While Dendreon awaits data to complete the prostate cancer vaccine’s BLA, other candidates progress.

House Panel Denies Members' Request To Investigate Provenge Advisory Committee

Bipartisan group looking to investigate conflict of interest at an FDA advisory committee on Provenge were stopped in their tracks by a letter from Energy & Commerce Committee leaders.

Related Content

Topics

UsernamePublicRestriction

Register

PS066124

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel